Patents protect scientific discoveries and are an essential link between basic research and new therapeutics. 

Currently Available Licensing Opportunities:

1) CD38 modulated chemotaxis (US patent 6,955,884)

2) A new calcium channel and chemotaxis inhibitor (patent pending)

3) Interleukin-15: a novel target for anemia therapeutics (patent pending)

4) NP-specific antibodies for the prevention and treatment of influenza (patent pending)

5) Vaccines and therapeutics for schistosomiasis (US patent 7,695,933)

6) A novel IL-12 receptor splice variant (patent pending)

To learn more the technologies listed above, please click the associated links.  For more information about Technology Transfer at Trudeau Institute, please contact:

Steve Smiley, Ph.D.
Director, Corporate Relations
ssmiley@trudeauinstitute.org
1-800-638-6064